Deborah A. Marshall, PhD

Despite universal access to HER2 testing in Ontario, variability in reporting by region and disease severity presents challenges for program evaluation and quality improvement initiatives.

Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.

Osteoporosis treatment for high-risk women is cost-effective, with bisphosphonates providing the most benefit at the lowest cost.